The changing landscape of medical practices coupled with an ongoing quest for innovative curative solutions are among the factors that define dynamics prevailing within the Plasma Therapy industry. Often known as convalescent plasma therapy, it refers to using blood serum from those who have been cured of certain infections to treat others. One primary driver behind some developments in this field relates to an urgent call for alternative therapeutic approaches that can cure, especially during pandemics, epidemics, etc. It gained popularity following its effectiveness against numerous viral infections, including the Covid-19 pandemic. Plasma therapy entails the extraction of plasma from recovered persons and reintroduction of it into patients with the disease in order to facilitate an immune response. This accelerated research and adoption of plasma therapy as a potential therapeutic intervention, especially during the COVID-19 pandemic.
Market dynamics are shaped by research and clinical trials. The scientific community's investigation into various conditions where plasma therapy can be used safely has contributed to this changing landscape. Regulatory approvals and guidelines influence market dynamics. Like any other medical intervention, plasma therapy undergoes regulatory scrutiny to ensure its safety and efficacy. Approval by regulatory bodies for specific indications is a significant determinant of market dynamics because it gives the green light for their use within healthcare settings. Another influence on market dynamics is the availability and accessibility of plasma therapy. An effort to establish a strong infrastructure for collecting, processing, and distributing plasma affects how widely this kind of treatment is embraced across care systems. This involves engagement among health organizations, blood banks, and scientific research groups, hence creating a full-range system that supports the provision of convalescent plasma for curative purposes.
Collaborations and partnerships mark the competition in the plasma therapy market. It is through cooperation between research institutions, pharmaceutical companies, and healthcare organizations that they share their resources and expertise. Again, public awareness and perception also affect market dynamics. The circulation of information on successful cases of plasma therapy treatment of certain diseases increases the interest and demand of patients. There is, therefore, a need for effective communication regarding benefits and limitations, as well as ongoing research on plasma therapy, to influence views about it among health experts with regard to its adoption as a treatment option. Also worth noting is that economic considerations within this field impact market dynamics. Thus, affordability coupled with the cost-effectiveness of using plasma therapies influences their widespread use and application as treatment options. This has led healthcare providers to evaluate whether or not it would be economically viable to adopt plasma therapy into their mainstream medical practices, thus impacting its global inclusion in health systems.
The global plasma therapy market is expected to cross USD 1.15 Billion by 2032 at a CAGR of 13.8%. Plasma therapy can replace missing or deficient proteins that allow individuals to lead healthy and disorder-free lives. Due to increasing plasma-fractionation techniques, human blood produces several plasma-derived therapies for debilitating, chronic, and life-threatening disorders. Plasma products play a crucial role in medical treatment and prophylaxis.
Plasma products are critical for managing bleeding emergencies, autoimmune disease, and a number of chronic conditions that include hemophilia, congenital and acquired immunodeficiencies. The increased access to medical care, new products and applications, and diagnostic advances fuel the growth of the plasma therapy market. According to the Plasma Protein Therapeutics Association, the United States was the largest contributor to the global source plasma supply in 2017. Favorable regulatory guidelines increased the availability of donors whereas efficient plasma collection infrastructure fuel the plasma therapy market worldwide.
A group of international scientists has reportedly developed an alternative to antibiotics for treating chronic wounds based on activated wound dressing using ionized gas, as reported in 2024. Leading the study were Researchers from the University of Sheffield and the University of South Australia. The treatment involves the plasma activation of hydrogel dressings (that are commonly used in wound dressings) with a unique mix of different chemical oxidants that are effective in decontaminating and aiding healing in chronic wounds.
PAtlas Health Medical Group announced Platelet-rich Plasma (PRP) Microneedling Facelifts for patients in February 2021.
In October 2021, BioLife Plasma Services(US), to meet the growing demand for plasma-related therapies, opened a new plasma center in Worcester.
In the Czech Republic, Biotest AG of Germany opened the sixth center for plasma collection in August 2021 to ensure an uninterrupted supply of plasma through the addition of more centers.
EmCyte completed the acquisition of Cellmedix Holdings LLC in February 2020 involving all the assets of this US-based company including its proprietary product system namely Centrepid Platelet Concentrator.
In July 2020 - Grifols , one of the leading producers of plasma derived medicines signed an agreement with GC pharma for taking over a plasma fractionation facility based at Montreal along with other two purification facilities based at US and other two collections of plasma among others were able to expand their limits and boost market revenue through this strategic move which maintained their top position.
China Biologic Products Holdings, Inc., based in China, is a company that operates entirely from plasma and deals with the manufacturing of biopharmaceuticals, which merged with CBPO Group Limited in April 2020, hence expanding its product portfolio.
In March 2020, Takeda Pharmaceutical Company Limited started developing anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)- TAK-888 for treating coronavirus (COVID-19). Pharmaceutical companies' initiatives expedited the treatment development procedure against COVID-19, which led to better disease management.
COVID-19 Analysis
The COVID-19 pandemic outbreak, along with lockdowns imposed by governments to manage the spread of the disease, impacted several industries. The rise in infected patients impacted the management of hospitals because of its limited staff and resources in comparison to the sudden increase in the number of infected patients; this caused delayed medical procedures and surgeries. The non-emergency medical procedure was delayed, and emergency procedures that would have affected patients or could have caused loss of life if not carried out were prioritized.
The COVID-19 pandemic applied additional stress on the plasma supply. Companies, suppliers, and business owners of platelet-rich plasma (PRP) therapy products in Asian economies were affected by the sudden rise in COVID-19 patients. The middle- and low-income countries had to face challenges due to the lack of health infrastructures and regulations imposed by the governments on industries and suppliers. During pandemic, plasma therapy was proposed for the treatment because of the absence of vaccines, other specific drugs, and treatment.
Drivers
Market Restraints
Technology Analysis
Plasma therapy performs the replacement of deficient or missing proteins found in plasma to enable its receivers to live healthier and disorder-free lives. The therapy is used to treat various diseases such as arthritis, nutritional deficiency, bone repairing, and others. The therapy is also used for research purposes to study the effect of various viruses as well as bacteria on the body, along with bodies response to the diseases. The previously infected person's plasma contains antibodies against the diseases. These antibodies can be used for the treatment of diseases. COVID-19 outbreak witnessed plasma therapy as a potential cure for the disease. The use of plasma from the infected person for newly infected patient showed an increase in the immune response against the virus. Doctors worldwide used plasma therapy to treat highly infected people, which reduced the mortality rate effectively.
North America held the largest plasma therapy market share in 2020, owing to the availability of leading platelet-rich plasma therapy product manufacturers, active participation of research and academic institutes to conduct advanced research and development activities, rising awareness toward benefits of platelet-rich plasma therapies, and assistance from regulatory authorities and government to encourage the use of PRP for medical applications. The well-developed healthcare infrastructure in the region, along with the availability of highly skilled professionals is further contributing to the market growth.
Asia-Pacific
The high population in the region and the constant emergence of chronic diseases are the major factors boosting the market growth in the region. The developing healthcare facilities and active government participation for the improvement of public health is providing huge opportunities for the market. The outbreak of COVID-19 has enhanced the awareness regarding plasma therapy as is used a potential treatment. India was one of the forerunning countries to adapt the therapy. The large number of disease patients in the region is a key contributor to the regional market growth. An increase in investment by the major market players in the region is also boosting the market in Asia-Pacific.
Competitive Landscape
The global plasma therapy market has several key players. This demonstrates high competition in the market. The major market players in global plasma therapy market are BioLife Plasma Services (US), Cambryn Biologics LLC (US), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB S.A (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), Octapharma (Switzerland), Arthrex, Inc. (US), DePuy Synthes Companies (US), Grifols S.A (Spain), Global Stem Cells Group, Inc. (US), Juventix Regenerative Medical LLC (U.S.), and Celling Biosciences, Inc. (U.S.). These industry players are coming up with various business strategies to increase their market presence. The companies invest in R&D activities to expand their product portfolio, further driving the plasma therapy market. In addition, the market players are adopting various strategies such as mergers & acquisitions, contractual agreements, new product launches, increasing investments in R&D, and partnering with other players to expand their global footprint.
List of Key Companies Covered in this Report:
Recent Developments
Report Overview
The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, value chain, and impact of COVID-19 on the market.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)